<DOC>
	<DOCNO>NCT02065739</DOCNO>
	<brief_summary>The purpose study assess effect repeat administration 200 mg itraconazole single-dose pharmacokinetics JNJ-42165279 healthy male participant .</brief_summary>
	<brief_title>A Study Investigate Effects Itraconazole Pharmacokinetics JNJ-42165279 Healthy Male Participants</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , study healthy male participant . This study consist screen phase ( 21 2 day prior first dose administration JNJ-42165279 ) , 2-period ( Period 1 : Day 1 Day 3 Period 2 : Day 4 Day 10 ) open-label treatment phase , follow-up phase ( within 7 14 day last dose JNJ-42165279 ) . A single 30-mg dose JNJ-42165279 administer Day 1 Period 1 . During Period 2 , administration oral itraconazole 200 mg day start Day 4 . A second single oral 30-mg dose JNJ-42165279 administer Day 8 together dose 200 mg itraconazole . Sixteen healthy participant enrol study . Safety assessment include assessment adverse event , supine vital sign , 12-lead electrocardiogram , clinical laboratory test physical examination . The maximum study duration participant approximately 7 week .</detailed_description>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Body mass index ( BMI ) 18 30 kg/m2 inclusive ( BMI = weight/height2 ) Nonsmoker ( smoke 3 month prior screen ) During study 3 month receive study medication , must agree use adequate contraception method ( eg , vasectomy , doublebarrier , partner use effective contraception ) , always use condom sexual intercourse donate sperm Participants must sign informed consent document indicate understand purpose procedure require study willing participate study comply study procedure restriction Clinically significant abnormal value hematology , clinical chemistry urinalysis screen admission Clinically significant abnormal physical examination , vital sign 12lead electrocardiogram screen Day 1 , predose History current significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematological disease , lipid abnormality , bronchospastic respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , Parkinson 's disease , infection . History epilepsy fit unexplained blackouts Drinks , average , 8 cup ( equal 150 mL ) caffeine contain beverage per day Clinically significant acute illness within 7 day prior study drug administration Has contraindication use itraconazole antifungal azoles</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Healthy</keyword>
	<keyword>JNJ-42165279</keyword>
	<keyword>Itraconazole</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>